Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.65 |
| ▸ | KAT2A | Q92830 | 4/20 | 0.65 |
| ▸ | EP300 | Q09472 | 3/20 | 0.65 |
| ▸ | APEX1 | P27695 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.57 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.57 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17244078 | 0.89 | KAT2B (0.76) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL4797604 | 0.85 | MEN1 (0.68) | KAT2BCREBBPKAT2AEP300MEN1 | |
| SCHEMBL14252589 | 0.85 | MEN1 (0.68) | KAT2BCREBBPKAT2AEP300MEN1 | |
| SCHEMBL4797610 | 0.85 | MEN1 (0.68) | KAT2BCREBBPKAT2AEP300MEN1 | |
| SCHEMBL17830703 | 0.84 | MEN1 (0.70) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL17830707 | 0.81 | APEX1 (0.61) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL13362124 | 0.79 | PIM1 (0.64) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL13362135 | 0.77 | APEX1 (0.52) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL31284034 | 0.75 | APEX1 (0.92) | KAT2BCREBBPKAT2AEP300APEX1 | |
| SCHEMBL12934213 | 0.74 | MEN1 (0.68) | KAT2BCREBBPKAT2AEP300APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759384-B2 | Oxo-imidazolyl compounds | ASTEXPHRMACEUTICALS, INC. | 2014-06-24 | — | — | US | disclosed |
| US-8759384-B2 | Oxo-imidazolyl compounds | ASTEXPHRMACEUTICALS, INC. | 2014-06-24 | — | — | US | disclosed |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | THE ROCKEFELLER UNIVERSITY (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | THE ROCKEFELLER UNIVERSITY (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026009-A2 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | AVACYN PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | ASTEXPHRMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | ASTEXPHRMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | GALE, CYP51A1, GNE | KAT2B 2541/4885CREBBP 1540/4885KAT2A 1283/4885 |
| US-20140073639-A1 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE | GALE, ENGASE, MGAM | KAT2B 4209/4885CREBBP 532/4885KAT2A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.